

# *Pharmaceutical Economics & Health Policy*

## *Editorial Comment*

The effect of pharmacotherapeutic alternatives on health service expenditures in renal transplantation is assessed by Dr. Schommer and colleagues (p. 749). Drs. Wagner and O'Hara (p. 770) compare economic consequences associated with the selection of induction anesthesia in outpatient laparoscopic gynecologic surgery.

The translation, validation, and utility of a Spanish version of the American Urological Association Symptom Index are presented by Dr. Arocho and colleagues (p. 777). Dr. Rascati (p. 786) examines the extent of required concomitant pharmacotherapy for anxiety and/or sleep induction among Medicaid beneficiaries prescribed a specific serotonin-reuptake inhibitor or clomipramine. Finally, Mr. Tancer (p. 791) provides a historical chronology as to the emergence of pharmaceutical commerce in Cuba and the policy implications for health care in the region.

I trust the readership will find these articles to be of interest and value.

David Alexander Sclar, BPharm, PhD  
Section Editor